By Querida Anderson

The latest business and financial biotech news. In this issue: 1) Adherex Buys Back GSK%u2019s Rights to Failed Cancer Drug 2) Archemix and Merck Partner on Aptamer-Based Cancer Therapeutics, and more

News items reported in this issue: 1) 186-Gene Signature in Cancer Stem Cells Predicts Recurrence 2) National Prostate Cancer Coalition Commences Clinical Trial Education Program 3) Concomitant High-Dose Radiation Therapy Plus Cetuximab Improves Locoregional Control and Reduces Mortality, with No Increase in Radiation Therapy%u2013Associated Toxicity in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck, and more

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotechnology sector. In this issue: 1) Avalon Could Earn More Than $200M in Deal with Merck & Co. 2) OXiGENE Sets Fiscal 2007 Priorities 3) Genentech Shares Fall Nearly 3% on Avastin Study, and more

News reports featured in this issue: 1) Breast Cancer Spotlight 2) Expert Cancer Centers Cost-Effective for Managing Ovarian Cancer 3) New Breathalyzer

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Aveo Lands $477M Deal with Schering Plough 2) Eisai Grows Pharma-Based Cancer Pipeline in $325M Acquisition of Morphotek, and more

The Clinical Trials reported in this issue include: PHASE I: 1) Adherex Initiates Combination Trial of ADH-1 and Melphalan for Melanoma Treatment 2) Erimos Initiates Evaluation of First-In-Class Small Molecule Therapy for Glioma Brain Tumors PHASE II: 1) ChemGenex Treats First Patient in CML Trial, and more

Physicians' Financial News focuses on news-making and/or notable companies in the oncology/biotech sector. In this issue: 1) Cell Therapeutics' Indolent NHL Agent Gets Fast Tracked 2) First Low-Molecular-Weight Heparin Approved for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer, and more

The Clinical Trials reported in this issue are: PHASE I: CuraGen, TopoTarget Begin Study of HDAC Inhibitor Candidate as Combination Therapy for Soft Tissue Sarcomas Ambrilia%u2019s Therapeutic Peptide Shows Clinical Activity in Metastatic Prostate Cancer Patients PHASE II: Alchemia%u2019s Precursory Evaluation of mCRC Study Presents Positive Efficacy Data IsoRay%u2019s Cesium-131 Established as Front-Line Treatment for Early-Stage Prostate Cancer, and more

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) Amgen: Amgen Oncology Under Review 2) Myriad Genetics, Inc.: Launches Test to Predict Toxicity to 5-FU 3) GPC Biotech AG: Pulls NDA for Prostate Cancer Drug, and more

The Clinical Trials reported in this issue include: PHASE IV: Obesity a Major Risk Factor for Multiple Myeloma PHASE III: 1) Long-Term Safety of Adjuvant Trastuzumab (Herceptin) 2) Bevacizumab (Avastin) Helps Slow Tumor Growth in Patients with Advanced or Recurrent Non-Small-Cell Lung Cancer 3) Addition of Bevacizumab To Interferon Alfa 2a Nearly Doubles Median Progression-Free Survival in Patients with Previously Untreated Advanced Kidney Cancer, and more

Physicians' Financial News focuses on newsworthy and/or notable companies in the oncology/biotech sector. In this issue: 1) GlaxoSmithKline 2) Ventana Medical Systems Inc. and Roche Holding AG, and more

Among the Clinical Trials reported in this issue are: PHASE III: 1) More Positive News in GPC Biotech's Trial With Satraplatin 2) Sanofi-Aventis Presents Positive Results in Three Oncology Programs 3) Imatinib (Gleevec) After GIST Surgery Achieves Significant Survival Benefit, and more